Background: Cannabidiol (CBD) from hops (Humulus lupulus)—known as Kriya® Hops CBD—is a non-cannabis–derived cannabidiol product with high bioactivity (96.3%). Many psychiatric patients seek natural, non-cannabis alternatives foranxiety and insomnia. This study evaluates the clinical effects of Kriya® Hops CBD as an adjunct to treatment as usual in a real-world psychiatric setting. Methods: A retrospective chart review was conducted at a large integrative psychiatric clinic in Fort Collins, Colorado. Adult patients with clinician-diagnosed anxiety or sleep disorders who received Kriya® Hops CBD for ≥1 month were included. Outcomes were measured monthly using the Hamilton Anxiety Rating Scale (HAM-A) and the Pittsburgh Sleep Quality Index (PSQI). Descriptive statistics were performed. Results: The final sample consisted of 143 adults (94 anxiety; 49 sleep). Most received 25 mg/day of Kriya® Hops CBD. At the first monthly follow-up, 79.2% showed improvement in anxiety and 66.7% showed improvement in sleep. Significant improvement occurred in 15.3% (anxiety) and 25.0% (sleep). Anxiety improvements were rapid and sustained over 3 months, while sleep improvements were present but less stable. Treatment was well tolerated with minimal side effects. Conclusion: Kriya® Hops CBD demonstrated favorable tolerability and clinically meaningful improvements in anxiety and sleep within a naturalistic psychiatric setting. Compared to existing literature on cannabis-derived CBD, benefits were observed at substantially lower doses, suggesting higher clinical potency. Prospective controlled trials are warranted.